David A. Smith

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González de Castro et al. · The Lancet Oncology · 2013 · 728 citations

Medicine, Oncology, Pharmacology +13

Unilateral Transforaminal Posterior Lumbar Interbody Fusion (TLIF): Indications, Technique, and 2-Year Results

Thomas G. Lowe, A. David Tahernia, Michael O’Brien et al. · Journal of Spinal Disorders & Techniques · 2002 · 247 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus

M. Azim Ansari, Vincent Pedergnana, Camilla L. C. Ip et al. · Nature Genetics · 2017 · 146 citations · Full text

Life Sciences, Genetics, Immunology +17

An immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expression

Eddie Cano-Gamez, Katie L. Burnham, Cyndi Goh et al. · Science Translational Medicine · 2022 · 102 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors

David A. Smith, Andrea Magrì, David Bonsall et al. · Hepatology · 2018 · 92 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17